Previously, it has been shown the EGFR inhibitors lapatinib (EGFR), erlotinib (EGFR), afatinib (ErbB1, 2 and 4), gefitinib (EGFR) and dacomitinib (ErbB1-4), all of which have a quinazoline scaffold like sapitinib, are orally efficacious for the treatment of certain types of human cancers (25). This evidence concerns the gene EGFR and cancer.